A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant
A study for postmenopausal women with advanced or metastatic breast cancer using study drug MLN0128
Sponsor: Millennium Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAN6701
U.S. Govt. ID: NCT02049957
Contact: Kevin Kalinsky: 2123050170 / kk2693@columbia.edu
Additional Study Information: This study involves research; it is the first time that MLN0128 will be studied in patients who are also receiving antihormonal medication. The main purposes of the study are to determine: The risks and discomforts of MLN0128 when given with antihormonal medication. Whether giving MLN0128 in combination with antihormonal medication affects the growthof your tumor(s). How much MLN0128 is in your blood and how your body gets rid of MLN0128 (known aspharmacokinetic or PK measurements). For some patients receiving exemestane asantihormonal medication, the amount of exemestane is in your blood will also be evaluated. How treatment with MLN0128 may affect proteins that are involved in how the study drugworks in the body.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Have you had any recent anticancer therapy or other investigation therapy within the past few weeks? Yes No
Do you have advanced or metastatic breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Kevin Kalinsky
kk2693@columbia.edu
2123050170
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE